Duyuru • Jul 01
CollPlant Biotechnologies Ltd. announced that it expects to receive $2.600001 million in funding CollPlant Biotechnologies Ltd. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 7,647,061 ordinary shares at an issue price of $0.34 per ordinary share (or ordinary share equivalents in lieu thereof), at an issue price of $0.3399 per ordinary share equivalent and unregistered series A warrants to purchase up to 7,647,061 ordinary shares and unregistered series B warrants to purchase up to 15,294,122 ordinary shares for total gross proceeds of $2,600,000.74 on June 30, 2026. The series A warrants will have an exercise price of $0.34 per share, will be exercisable on the date of shareholder approval (the "Shareholder Approval Date") and will expire two years after the effective date of a registration statement registering the shares issuable upon exercise of the warrants. The series B warrants will have an exercise price of $0.34 per share, will be exercisable on the Shareholder Approval Date and will expire five years after the effective date of a registration statement registering the shares issuable upon exercise of the warrants. The private placement is expected to close on or about July 1, 2026, subject to the satisfaction of customary closing conditions. The offer and sale of the foregoing securities is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder, and applicable state securities laws, and the securities have not been and will not initially be registered under the Securities Act, or applicable state securities laws. New Risk • May 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (US$389k revenue). Market cap is less than US$10m (US$5.79m market cap). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). New Risk • Apr 23
New major risk - Revenue and earnings growth Earnings have declined by 26% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 26% per year over the past 5 years. Market cap is less than US$10m (US$5.66m market cap). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Revenue is less than US$5m (US$2.4m revenue). Breakeven Date Change • Apr 13
No longer forecast to breakeven The analyst covering CollPlant Biotechnologies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of US$5.03m in 2028. New forecast suggests the company will make a loss of US$10.3m in 2028. Reported Earnings • Mar 27
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: US$0.94 loss per share (improved from US$1.45 loss in FY 2024). Revenue: US$2.37m (up 360% from FY 2024). Net loss: US$11.5m (loss narrowed 31% from FY 2024). Revenue missed analyst estimates by 46%. Earnings per share (EPS) exceeded analyst estimates by 4.1%. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings. Duyuru • Mar 11
CollPlant Biotechnologies Ltd. to Report Fiscal Year 2025 Results on Mar 26, 2026 CollPlant Biotechnologies Ltd. announced that they will report fiscal year 2025 results Pre-Market on Mar 26, 2026 Duyuru • Feb 26
Collplant Biotechnologies Announces Korean Patent Allowance Secured for Its Photocurable Dermal Filler CollPlant Biotechnologies announced that the Korean Patent Office has allowed a patent application covering key aspects of the Company's photocurable dermal filler technology currently under development for the aesthetic market. The allowed patent application covers a polymerizable solution and its use in tissue augmentation. The composition is injected into a sub-epidermal tissue space and subsequently polymerized in situ using external light activation. This invention underpins CollPlant's proprietary photocuring platform for dermal fillers. CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, announced that the Korean Patent Office has allowed a patent application covering key aspects of the Company's photocurable dermal filler technology currently under development for the aesthetic market. The allowed patent application covers a polymerizable solution and its use in tissue augmentation. The composition is injected into a sub-epidermal tissue space and subsequently polymerized in situ using external light activation. This invention underpins CollPlant's proprietary photocuring platform for dermal fillers. Duyuru • Feb 24
CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-To-Print BioFlex CollPlant announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications.BioFlex is engineered to support the biofabrication of advanced tissue models for drug discovery, as well as the development of engineered tissues and transplantable organs. This ready-to-print system includes Collink.3D™ 50, a biodegradable polymer component, together with proprietary photoactive agents optimized for high-resolution DLP printing.By following the BioFlex formulation and printing guidelines, users can efficiently generate customized, high-performance bioinks with tunable mechanical properties, enabling precise fabrication of complex, biologically relevant structures. This integrated solution eliminates the need for extensive component screening and streamlines formulation development, enabling researchers and industry partners to significantly reduce development time while achieving constructs with precisely controlled physical properties, including enhanced tensile strength, elasticity, reduced brittleness, and improved structural integrity.Designed to serve both academic laboratories and industrial R&D environments, BioFlex supports advanced applications in 3D bioprinting, tissue engineering, and regenerative medicine, facilitating faster translation from concept to functional tissue constructs. Duyuru • Feb 17
Collplant Biotechnologies, Inc. Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments CollPlant Biotechnologies announced the strategic positioning of its photocurable dermal filler platform to address facial volume loss associated with rapid weight reduction, including patients treated with GLP-1 therapies. The expanding use of GLP-1 therapies for metabolic health and weight management has created a growing population experiencing loss of facial fat, skin laxity, and structural inflation - commonly referred to in the medical community as weight-loss-related facial volume depletion. CollPlant's photocurable dermal filler is designed to restore volume while providing a supportive regenerative matrix that integrates with surrounding tissue. Industry experts report growing interest in non-surgical treatments that restore volume while maintaining natural facial dynamics. CollPlant believes its regenerative biomaterial platform positions the company to address this emerging clinical and aesthetic need. Development Status and Strategic Vision: CollPlant is advancing its photocurable filler technology, which is in the preclinical stage, as part of its broader strategy to develop next-generation regenerative aesthetic solutions based on rhCollagen, including applications targeting age-related volume loss, skin regeneration, structural soft tissue restoration, and weight-loss-associated facial changes. The company continues to evaluate clinical and commercial opportunities for its photocurable filler platform and plans to further explore its potential role in addressing evolving patient needs in the rapidly growing aesthetic medicine market. New Risk • Feb 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Significant insider selling over the past 3 months (US$337k sold). Revenue is less than US$5m (US$2.5m revenue). Market cap is less than US$100m (US$11.5m market cap). New Risk • Feb 06
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.58m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (US$9.58m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$1.1m net loss in 3 years). Significant insider selling over the past 3 months (US$337k sold). Revenue is less than US$5m (US$2.5m revenue). Duyuru • Feb 05
CollPlant Biotechnologies Ltd. has filed a Follow-on Equity Offering in the amount of $2 million. CollPlant Biotechnologies Ltd. has filed a Follow-on Equity Offering in the amount of $2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,600,000
Price\Range: $1.25
Discount Per Security: $0.0875
Transaction Features: Registered Direct Offering Major Estimate Revision • Dec 03
Consensus revenue estimates fall by 51% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$9.00m to US$4.40m. Forecast losses increased from -US$0.315 to -US$0.75 per share. Biotechs industry in the US expected to see average net income decline 6.9% next year. Consensus price target of US$11.56 unchanged from last update. Share price fell 4.5% to US$2.14 over the past week. Reported Earnings • Nov 28
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: US$0.27 loss per share (improved from US$0.38 loss in 3Q 2024). Revenue: US$77.0k (up US$73.0k from 3Q 2024). Net loss: US$3.48m (loss narrowed 20% from 3Q 2024). Revenue missed analyst estimates by 98%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Duyuru • Nov 28
CollPlant Biotechnologies Ltd., Annual General Meeting, Dec 31, 2025 CollPlant Biotechnologies Ltd., Annual General Meeting, Dec 31, 2025. Location: offices of goldfarb gross seligman & co., one azrieli center, round building, 40th floor, tel-aviv Israel Duyuru • Nov 18
CollPlant Biotechnologies Ltd. to Report Q3, 2025 Results on Nov 26, 2025 CollPlant Biotechnologies Ltd. announced that they will report Q3, 2025 results Pre-Market on Nov 26, 2025 Duyuru • Oct 21
Collplant Biotechnologies Announces Positive Results from A Head-To-Head Comparative Study of Itsrhcollagen-Based Bioink, Collink.3D, and Matrigel®? CollPlant Biotechnologies announced positive results from a head-to-head comparative study of its rhCollagen-based bioink, Collink.3D™?, and Matrigel®?, conducted by the Levenberg Lab at Technion - Israel Institute of Technology. Matrigel®?, developed and marketed by Corning, has been one of the most widely used extracellular matrices for more than three decades. Derived from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, it contains a rich combination of basement membrane proteins such as laminin, collagen IV, heparan sulfate proteoglycans, and entactin/nidogen, as well as growth factors that make it a cornerstone for 3D cell culture, disease modeling, and drug discovery. In the Technion study, Collink.3 D™? demonstrated enhanced mechanical strength, elasticity, and stability, providing a reproducible environment that supports organized and long-lasting tissue formation. It supports the creation of complex 3D architectures with defined geometric, physical, and biological properties - offering a sustainable and high-performance solution for the rapidly growing field of regenerative medicine. Duyuru • Oct 16
CollPlant Biotechnologies Announces First-In-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers Using RhCollagen-Based BioInk CollPlant Biotechnologies announced that, according to a scientific article published in the Archives of Dermatological Research, researchers from Mayo Clinic have developed the first fully humanized 3D bioprinted skin model using CollPlant's plant-derived rhCollagen. The model represents an innovative alternative to animal testing for preclinical research, with broad potential applications in cosmetic and pharmaceutical testing, disease modeling, and drug development. The integration of these constructs into a skin-on-a-chip system enables the evaluation of topical and transdermal drug delivery in a non-animal model. In addition, the 3D bioprinting of skin using plant-derived rhCollagen presents significant advantages, including high-throughput production of personalized human skin models, and potential applications in regenerative medicine and other areas of medicine. Duyuru • Oct 01
CollPlant Biotechnologies Announces Positive Results from Non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler CollPlant Biotechnologies announced positive results from its non-clinical program evaluating its photocurable dermal filler, as well as plans to advance this product candidate into clinical trials. This novel filler represents a significant breakthrough in aesthetic medicine by uniquely integratingouring precision, structural support, and tissue regeneration into a single treatment. CollPlant's formulation combines hyaluronic acid with a modified form of rhCollagen to deliver both immediate and long-lasting benefits. CollPlant's non-clinical program included a comprehensive set of safety and performance evaluations: a one-year, in vivo study confirming long-term durability; biocompatibility assessments demonstrating compliance with international relevant standards. The combined results obtained establish a strong foundation for clinical advancement, and CollPlant is now scaling and optimizing its manufacturing process to ensure readiness for the upcoming clinical trial. Price Target Changed • Sep 15
Price target decreased by 17% to US$11.56 Down from US$14.00, the current price target is an average from 2 analysts. New target price is 340% above last closing price of US$2.63. Stock is down 47% over the past year. The company is forecast to post a net loss per share of US$0.32 next year compared to a net loss per share of US$1.45 last year. Breakeven Date Change • Sep 15
No longer forecast to breakeven The 2 analysts covering CollPlant Biotechnologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$551.2k in 2026. New consensus forecast suggests the company will make a loss of US$2.92m in 2027. Duyuru • Aug 05
CollPlant Biotechnologies Ltd. to Report Q2, 2025 Results on Aug 20, 2025 CollPlant Biotechnologies Ltd. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025 Duyuru • Jul 16
Collplant Biotechnologies Ltd. Appoints Bowman Bagley as Head of North America Commercial Operations CollPlant Biotechnologies announced the appointment of Bowman Bagley as Vice President, Commercial North America. In this newly created role, Mr. Bagley will lead the company's commercial strategy and execution in North America, including sales and marketing, logistics, and expansion of market presence for CollPlant's rhCollagen-based products and platforms. Mr. Bagley joins CollPlant from Wasatch Biolabs, a genomics research company, where he served as Vice President and Fractional CxO, leading revenue operations and growth initiatives. Previously, he spent nearly a decade at Advanced BioMatrix, a global supplier of purified collagen and extracellular matrix products, where he served as Chief Executive Officer. During his tenure, he held leadership roles across product development, business development, and global sales, helping to establish the company as a leading supplier in the research and tissue engineering space. In addition to his leadership roles, Mr. Bagley has advised life science companies on go-to-market strategies, commercial partnerships, and scaling operations. He is also an active angel investor with NuFund Venture Group, where he conducts due diligence on emerging biotech ventures. Mr. Bagley holds a B.S. in Neuroscience from Brigham Young University and an MBA from the University of Utah. Duyuru • Jun 04
CollPlant Biotechnologies Announces European Patent Acceptance Secured for Its Collaboration Multiple as Soft Tissue Fillers and Implants CollPlant Biotechnologies announced that the European Patent and Tradark Office has allowed a patent application related to CollPlant's injectable fillers and regenerative breast implant candidates, being developed for the aesthetic and reconstructive procedures markets, respectively. This newly allowed patent application pertains to CollPlant's injectability soft tissue fillers as well as its organ manufacturing technology related to its regenerative breast implant pipeline currently under development. The European Patent Application is directed, among other things, to a 3D biocompatible and degradable soft tissue implant composed of a bioprinted scaffold and an injectable filler within it, each based on its recombant human collagen (rhCollagen). Utilization of photocuring technology is expected to ease the injection process, particularly in subcutaneous and supraperiosteal applications. As the product degrades, a newly formed tissue is expected to regenerate and take its place. Duyuru • May 31
CollPlant Biotechnologies Ltd. has filed a Follow-on Equity Offering in the amount of $3.600006 million. CollPlant Biotechnologies Ltd. has filed a Follow-on Equity Offering in the amount of $3.600006 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,200,002
Price\Range: $3
Transaction Features: Registered Direct Offering Duyuru • May 14
CollPlant Biotechnologies Ltd. to Report Q1, 2025 Results on May 28, 2025 CollPlant Biotechnologies Ltd. announced that they will report Q1, 2025 results Pre-Market on May 28, 2025 Duyuru • Apr 15
CollPlant's Collink.3D BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies CollPlant Biotechnologies commented following the United States Food and Drug Administration (FDA)'s step announced last week to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drug candidates with more effective, human-relevant methods. These systems can expedite the gap between benchtop studies and clinical trials, as well as be more economical and enable a reduced time to market. On April 10, 2025, the FDA announced a plan to phase out animal testing as a requirement for the pre-clinical development of monoclonal antibodies and other drugs. The FDA's statement specifies that within 3-5 years, animal testing may become the exception. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all, including uncertainties surrounding the methods of fundraising and the Company's preferences regarding such methods; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or Company's strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen-based BioInk and medical aesthetics products or product candidates including, but not Limited to, acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D Birinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company'sability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologi es; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in Israel; and the Company's ability to establish and maintain strategic partnerships, including its partnership with AbssVie and its ability to receive milestone and royalties payments over the AbbVie agreement. Duyuru • Mar 19
CollPlant Biotechnologies Ltd. to Report Q4, 2024 Results on Mar 26, 2025 CollPlant Biotechnologies Ltd. announced that they will report Q4, 2024 results Pre-Market on Mar 26, 2025 Duyuru • Nov 12
CollPlant Biotechnologies Ltd. to Report Q3, 2024 Results on Nov 27, 2024 CollPlant Biotechnologies Ltd. announced that they will report Q3, 2024 results Pre-Market on Nov 27, 2024 Duyuru • Aug 06
CollPlant Biotechnologies Ltd. to Report Q2, 2024 Results on Aug 20, 2024 CollPlant Biotechnologies Ltd. announced that they will report Q2, 2024 results Pre-Market on Aug 20, 2024 Duyuru • Jun 09
Collplant Successfully Bio-Prints 200Cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data CollPlant Biotechnologies announced that it has successfully printed for the first-time breast implants of 200 cc, which are commercial size. These implants were printed using CollPlant's proprietary rhCollagen bioinks. In addition, CollPlant announced additional, positive, interim preclinical data from ongoing large-animal studies, evaluating its regenerative breast implants. Currently there are no other commercial products that allow regeneration of soft tissues such as the breast. Additional positive data from CollPlant's pre-clinical studies that are currently underway show evidence of well-developed connective tissue containing blood vessels (i.e., neovascularization) within the implant. Progressing tissue ingrowth within the implant was also observed confirming tissue regeneration. An initial biodegradation process was observed, while preserving the original structure of the 3D breast implant. No adverse tissue reaction was observed, confirming the safety profile of this novel implant in development. The most common breast augmentation or reconstruction procedures now are based on synthetic silicone breast implantations, an artificial substitution for natural regenerated tissue with risks of complications. In the U.S. alone, hundreds of thousands of people per year experience adverse events that range from autoimmune symptoms to the very serious breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). CollPlant's rhCollagen-based, 3D-bioprinted breast implants that are comprised of CollPlant's proprietary plant-derived rhCollagen and other biomaterials, are expected to regenerate breast tissue without eliciting immune response, and therefore may provide a revolutionary alternative for aesthetic and reconstructive procedures, including postmastectomy for cancer patients. In addition, CollPlant's regenerative breast implants have the potential to provide a novel solution for women in the need for breast reconstruction and augmentation, the need of which is sizeable, as it is the second most common plastic surgery procedure that is performed worldwide today. In December of 2023, CollPlant initiated an additional large-animal study to evaluate commercial-size versions of the 3D-bioprinted, regenerative breast implants. This study will be used to obtain data to support subsequent human studies and future product commercialization. CollPlant expects to report topline data from this study, and an additional ongoing study, in the fourth quarter of this year and first quarter of next year. Duyuru • May 18
CollPlant Biotechnologies Ltd. to Report Q1, 2024 Results on May 29, 2024 CollPlant Biotechnologies Ltd. announced that they will report Q1, 2024 results Pre-Market on May 29, 2024 New Risk • Apr 05
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$7.0m Forecast net loss in 3 years: US$454k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$454k net loss in 3 years). Shareholders have been diluted in the past year (6.3% increase in shares outstanding). Market cap is less than US$100m (US$60.2m market cap). Reported Earnings • Apr 05
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: US$0.62 loss per share (improved from US$1.53 loss in FY 2022). Revenue: US$11.0m (up US$10.7m from FY 2022). Net loss: US$7.02m (loss narrowed 59% from FY 2022). Revenue missed analyst estimates by 43%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Board Change • Apr 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. CEO & Director Yehiel Tal was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Mar 28
CollPlant Biotechnologies Ltd. to Report Fiscal Year 2023 Results on Apr 04, 2024 CollPlant Biotechnologies Ltd. announced that they will report fiscal year 2023 results at 9:30 AM, US Eastern Standard Time on Apr 04, 2024 Duyuru • Jan 02
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants CollPlant Biotechnologies announced its initiation of a pre-clinical trial to evaluate commercial-size, 3D-bioprinted, regenerative breast implants. Currently, there are no commercial products that allow regeneration of soft tissues such as the breast. This would be paradigm-shifting in a market that has maintained such a large demand yet has seen increasing issues with safety over the last few decades. A primary goal of this study is to obtain data which would then support the optimization of the implant design and apply this design to a pivotal large-animal study that is intended to be the subject of discussions with the FDA." In the U.S. alone, hundreds of thousands of people each year experience adverse events that range from immune symptoms to the very serious breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). CollPlant's breast implants, comprised of the Company's proprietary plant-derived rhCollagen and other biomaterials, are expected to regenerate breast tissue without eliciting immune response and therefore may provide a revolutionary alternative for aesthetic and reconstructive procedures, including postmastectomy for cancer patients. In January 2023, CollPlant announced positive results from its first large-animal study, which demonstrated progressive stages of tissue regeneration after three months, as highlighted by the formation of maturing connective tissue and neovascular networks within the implants, with no adverse events reported. New Risk • Nov 30
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$6.7m Forecast net loss in 3 years: US$3.6m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$3.6m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Market cap is less than US$100m (US$61.3m market cap). Duyuru • Nov 10
CollPlant Biotechnologies Ltd. to Report Q3, 2023 Results on Nov 29, 2023 CollPlant Biotechnologies Ltd. announced that they will report Q3, 2023 results Pre-Market on Nov 29, 2023 New Risk • Nov 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Market cap is less than US$100m (US$61.2m market cap). Reported Earnings • Aug 25
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Second quarter 2023 results: EPS: US$0.51 (up from US$0.39 loss in 2Q 2022). Revenue: US$10.2m (up US$10.1m from 2Q 2022). Net income: US$5.76m (up US$10.0m from 2Q 2022). Profit margin: 57% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 98%. Earnings per share (EPS) also surpassed analyst estimates significantly. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Duyuru • Aug 10
CollPlant Biotechnologies Ltd. to Report Q2, 2023 Results on Aug 24, 2023 CollPlant Biotechnologies Ltd. announced that they will report Q2, 2023 results Pre-Market on Aug 24, 2023 Major Estimate Revision • Jun 27
Consensus estimates of losses per share improve by 43% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from US$15.3m to US$15.7m. EPS estimate increased from -US$0.105 per share to -US$0.06 per share. Biotechs industry in the US expected to see average net income decline 85% next year. Consensus price target of US$16.88 unchanged from last update. Share price rose 7.7% to US$8.23 over the past week. New Risk • Jun 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (US$666k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$753k net loss in 3 years). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (US$84.7m market cap). Duyuru • Jun 09
CollPlant Biotechnologies Ltd., Annual General Meeting, Jul 18, 2023 CollPlant Biotechnologies Ltd., Annual General Meeting, Jul 18, 2023, at 10:00 Israel Standard Time. Location: the offices of Goldfarb Gross Seligman & Co. at One Azrieli Center, Round Building, 40th Floor Tel - Aviv Israel Agenda: To approve the re-election of Dr. Roger Pomerantz, Dr. Abraham (Avri) Havron, Joseph Zarzewsky, Dr. Elan Penn, Hugh Evans, Alisa Lask and Mr. Yehiel Tal (who also serves as the Company’s CEO) to the board of directors of the Company, each until the next annual general meeting of shareholders (a separate vote for each director will be taken); to approve the re-appointment of Kost Forer Gabbay & Kasierer, a member firm of Ernst & Young Global, as the independent auditors of the Company for the period ending at the close of the next annual general meeting; to approve the adoption and the grant of a new letter of indemnification for the Company’s current and future directors and officers, other than to the Company’s current CEO, and subject to the approval of Proposal No. 4; and to consider other matters. Reported Earnings • May 26
First quarter 2023 earnings: EPS and revenues exceed analyst expectations First quarter 2023 results: US$0.33 loss per share (improved from US$0.36 loss in 1Q 2022). Net loss: US$3.72m (loss narrowed 3.8% from 1Q 2022). Revenue exceeded analyst estimates. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 10% per year. Reported Earnings • Mar 30
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: US$1.53 loss per share (down from US$0.024 profit in FY 2021). Net loss: US$16.9m (down US$17.2m from profit in FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.9%. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Duyuru • Jan 05
CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives CollPlant announced that it has successfully completed a large animal study for its recombinant human collagen (rhCollagen)-based 3D bioprinted regenerative breast implants, addressing the $2.5 billion global breast implant market. Supported by these promising results, the Company is planning to initiate a follow-up large animal study during 2023 using commercial-size implants to support subsequent human studies and future product commercialization. The objectives of the study were fully achieved, including the evaluation of the safety and efficacy of the bioprinted breast implants. The histological analysis of the implants demonstrated progressive stages of tissue regeneration after three months, as indicated by the formation of maturing connective tissues and neovascular networks. The development of native tissue was synchronized with the degradation process of the implant, which was consistent with the desired outcome observed during the trial. There was also no indication of adverse reaction noted within the implants and the surrounding tissue. The company's bioprinted regenerative implants aim to overcome the challenges of existing breast procedures using silicone implants or autologous fat transfer. According to the U.S. Food and Drug Administration, approximately 350,000 people have reported adverse events involving breast implants between 2009 and 2019. Reports range from autoimmune symptoms to breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The company's regenerative breast implants are comprised of the Company's proprietary plant-derived rhCollagen, an ideal building block for regenerative medicine implants attributed to better bio-functionality, superior homogeneity, and improved safety. The printed implant is designed to degrade over time while promoting natural tissue regeneration and integration with host tissue. 3D bioprinting technology enables scalable production of highly precise and repeatable constructs which can be customized to the individual anatomy of patients. In the product development process, the company uses modeling tools that enable an optimal design of the implant in terms of geometry, materials, physical properties, and biological environment. The modeling takes into consideration the internal anatomy of the breast tissue and the implant environment post-implantation. The implant testing is rigorous and includes static and dynamic loading in order to mimic breast tissue behavior under different conditions and comply with the most stringent safety requirements. The implants are designed to withstand physiological loads and to provide what the company believes is a safer, more natural, and long-lasting alternative to current breast reconstruction and augmentation procedures. Duyuru • Jan 04
Collplant Enriches Portfolio of Rhcollagen-Based Bioinks with Launch of Collink.3Dtm 50L in Powder Form CollPlant announced the launch of Collink.3DTM 50L, a recombinant human collagen (rhCollagen)-based bioink in a powder form for use in a wide range of 3D bioprinting applications, including drug discovery, drug screening, tissue testing as well as the development of transplantable tissues and organs. Collink.3DTM 50L, the result of a comprehensive development effort, is a tunable bioink that can be easily reconstituted to form solutions with application-specific concentrations, formulated with other components and crosslinked to form hydrogels that meet the demand for specific geometric, physical and biological properties of different 3D constructs. Collink.3D™ 50L adds to CollPlant's growing portfolio of commercial bioinks launched over the last year, Collink.3DTM 50 and Collink.3DTM 90. Biofabricated constructs composed of Collink.3DTM offer superior biological performance, consistency and safety. The Collink.3D™ platform is compatible with major 3D bioprinting technologies and cell types. Reported Earnings • Dec 02
Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.29 loss in 3Q 2021) Third quarter 2022 results: US$0.40 loss per share (further deteriorated from US$0.29 loss in 3Q 2021). Net loss: US$4.38m (loss widened 42% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Duyuru • Nov 08
Collplant Expands Rhcollagen-Based Bioink Platform with Launch of Collink.3D 90 CollPlant announced the Company is launching Collink.3DTM 90, a recombinant human collagen (rhCollagen)-based bioink for use in a variety of 3D bioprinting applications. Collink.3DTM 90 is complementary to the Company’s first commercial bioink, Collink.3DTM 50, which was launched late last year, offering increased mechanical properties to address additional printing requirements of soft and hard tissues. Bioinks are applied to a diverse range of soft and hard tissue engineering applications, with each tissue or organ having specific mechanical requirements for fulfilling physiological needs. Thus, the most suitable bioink is required for a given application to mimic the physical properties of the target tissue or organ, while ensuring high cell survival. Collink.3DTM 90 demonstrates faster human cell migration into gel matrices compared with a commercial hydrogel widely used for 2D and 3D cell culture. Cell migration plays a pivotal role in physiological processes such as tissue repair and regeneration, and these initial results indicate the potential for Collink.3DTM 90 to perform as a superior, animal free, human cell culture substrate. Collink.3DTM enables the high-resolution, scalable and reproduceable 3D bioprinting of scaffolds that accurately mimic the physical properties of human tissues and organs, with improved biofunctionality, safety and reproducibility. Applications for Collink.3D include its use in 3D cell culturing, tissue modeling for drug discovery and development, as well as engineering tissues and implantation of organs in regenerative medicine, representing a potential multi-billion-dollar market opportunity. Biofabricated constructs composed of Collink.3DTM offer superior biological performance, consistency and safety. Collink.3D is compatible with major 3D bioprinting technologies and cell types including stem cells, induced pluripotent stem cells, endothelial, and epithelial cells. Reported Earnings • Aug 26
First half 2022 earnings released: US$0.74 loss per share (vs US$0.91 profit in 1H 2021) First half 2022 results: US$0.74 loss per share (down from US$0.91 profit in 1H 2021). Net loss: US$8.15m (down 215% from profit in 1H 2021). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Duyuru • Jun 30
CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study CollPlant announced the initiation of a study in large animals for its 3D bioprinted regenerative breast implant program, addressing the $2.8 billion global breast implant market. CollPlant's bioprinted regenerative implants aim to overcome the challenges of existing breast procedures that use silicone implants or autologous fat transfer. According to the U.S. Food and Drug Administration, approximately 350,000 people have reported adverse events involving breast implants between 2009 and 2019. Reports range from autoimmune symptoms to breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). CollPlant's regenerative breast implants are comprised of the Company's proprietary plant-derived rhCollagen, an ideal building block for regenerative medicine implants attributed to better bio-functionality, superior homogeneity, and improved safety. The printed implant is intended to degrade over time while promoting natural tissue regeneration and integration with host tissue. 3D bioprinting technology enables scalable production of highly precise and repeatable constructs, which can be customized to the individual anatomy of patients. The implants are designed to withstand physiological loads and to provide what CollPlant believes is a safer, more natural, and long-lasting alternative to current breast reconstruction and augmentation procedures. In the product development process, CollPlant uses computational modeling tools that enable an optimal design of the implant in terms of geometry, materials, physical properties, and biological environment. The modeling takes into consideration the internal anatomy of the breast tissue and the behavior of an implant, post-implantation. The implant testing is rigorous and includes static and dynamic loading in order to mimic breast tissue behavior under different conditions and comply with the most stringent safety requirements. Reported Earnings • May 28
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: US$0.36 loss per share (down from US$1.20 profit in 1Q 2021). Net loss: US$3.86m (down 138% from profit in 1Q 2021). Revenue missed analyst estimates by 46%. Earnings per share (EPS) also missed analyst estimates by 7.4%. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 20
Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.10 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: US$140.0k (down 97% from 3Q 2020). Net loss: US$3.08m (down US$3.78m from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 52% per year whereas the company’s share price has increased by 48% per year. Recent Insider Transactions Derivative • Nov 20
Deputy CEO & CFO notifies of intention to sell stock Eran Rotem intends to sell 35k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of November. If the sale is conducted around the recent share price of US$21.65, it would amount to US$763k. As of today, Eran currently holds no shares directly (This sale likely refers to shares that have not yet been received). There have been no trades via on-market transactions or options from company insiders in the last 12 months. Recent Insider Transactions Derivative • Nov 12
Independent Director notifies of intention to sell stock Abraham Havron intends to sell 6k shares in the next 90 days after lodging an Intent To Sell Form on the 8th of November. If the sale is conducted around the recent share price of US$22.00, it would amount to US$132k. As of today, Abraham currently holds no shares directly (This sale likely refers to shares that have not yet been received). There have been no trades via on-market transactions or options from company insiders in the last 12 months. Valuation Update With 7 Day Price Move • Oct 22
Investor sentiment improved over the past week After last week's 22% share price gain to US$20.00, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 13x in the Biotechs industry in the US. Total returns to shareholders of 242% over the past three years. Reported Earnings • Aug 21
Second quarter 2021 earnings released: US$0.30 loss per share (vs US$0.28 loss in 2Q 2020) The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$691.0k (down 16% from 2Q 2020). Net loss: US$3.04m (loss widened 54% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 43% per year whereas the company’s share price has increased by 42% per year. 